The biotechnology and medtech sectors have traded down sharply over the past 18 months, creating a significant refinancing overhang in public markets and completely resetting valuation expectations, that are now far below the peak valuations seen in early 2021.

What will 2023 likely hold for life science entrepreneurs?

1. Is risk appetite picking up again?

2. Can life science entrepreneurs expect to benefit from this?

3. What is the consensus post the JP Morgan Conference?

4. What does the financing and re-financing landscape look like?

5. How can life science entrepreneurs create more financing optionality for their companies?

6. What appetite for M&A and partnering should we expect from big pharma and medtech?